Cogstate Ltd (ASX: CGS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

CogState Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $372.82 million
P/E Ratio 51.02
Dividend Yield N/A
Shares Outstanding 172.60 million
Earnings per share 0.030
Dividend per share N/A
Year To Date Return 94.55%
Earnings Yield 1.96%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Cogstate Ltd (ASX: CGS)
Latest News

CGS ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Cogstate Ltd

Cogstate Ltd is a cognitive science company. The principal activity of the company is the sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management,statistical analysis, and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.

CGS Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
26 Nov 2021 $2.14 $-0.08 -3.60% 295,719 $2.26 $2.26 $2.13
25 Nov 2021 $2.22 $0.01 0.45% 180,395 $2.28 $2.28 $2.19
24 Nov 2021 $2.21 $-0.11 -4.74% 143,425 $2.38 $2.38 $2.21
23 Nov 2021 $2.32 $-0.03 -1.28% 82,158 $2.38 $2.40 $2.31
22 Nov 2021 $2.35 $0.03 1.29% 26,936 $2.33 $2.39 $2.32
19 Nov 2021 $2.32 $-0.07 -2.93% 244,662 $2.40 $2.40 $2.32
18 Nov 2021 $2.39 $-0.01 -0.42% 206,590 $2.41 $2.45 $2.35
17 Nov 2021 $2.40 $0.00 0.00% 51,092 $2.38 $2.40 $2.24
16 Nov 2021 $2.40 $0.10 4.35% 1,434,110 $2.30 $2.45 $2.30
15 Nov 2021 $2.30 $-0.09 -3.77% 142,539 $2.40 $2.40 $2.29
12 Nov 2021 $2.39 $0.16 7.17% 126,961 $2.22 $2.39 $2.20
11 Nov 2021 $2.23 $-0.01 -0.45% 45,406 $2.22 $2.23 $2.21
10 Nov 2021 $2.24 $-0.02 -0.88% 38,473 $2.24 $2.24 $2.21
09 Nov 2021 $2.26 $0.05 2.26% 44,257 $2.22 $2.29 $2.20
08 Nov 2021 $2.21 $0.01 0.45% 48,083 $2.20 $2.25 $2.20
05 Nov 2021 $2.20 $-0.01 -0.45% 61,899 $2.21 $2.27 $2.20
04 Nov 2021 $2.21 $0.00 0.00% 137,304 $2.20 $2.22 $2.11
03 Nov 2021 $2.21 $-0.11 -4.74% 47,491 $2.32 $2.32 $2.21
02 Nov 2021 $2.32 $-0.01 -0.43% 8,296 $2.33 $2.33 $2.32
01 Nov 2021 $2.33 $-0.05 -2.10% 38,565 $2.40 $2.40 $2.27

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
11 Nov 2021 David Dolby Transfer 200 $446,000
As advised by the company. Correction of account designation
11 Nov 2021 David Dolby Transfer 200 $446,000
As advised by the company. Correction of account designation
12 Oct 2021 Richard van den Broek Buy 100 $84,000
Exercise of options.
12 Oct 2021 Richard van den Broek Exercise 100 $84,000
Exercise of options.
14 Sep 2021 Martyn Myer Sell 250 $442,733
On-market trade. Average Price
10 Sep 2021 David Dolby Exercise 100 $84,000
Exercise of options.
10 Sep 2021 David Dolby Buy 100 $84,000
Exercise of options.
10 Sep 2021 Martyn Myer Exercise 200 $168,000
Exercise of options.
10 Sep 2021 Martyn Myer Buy 200 $168,000
Exercise of options. As per announcement on 15/09/2021
01 Sep 2021 Kim Wenn Buy 11 $20,167
On-market trade. Average Price
23 Mar 2021 Bradley O'Connor Exercise 750 $630,000
Exercise of options.
23 Mar 2021 Bradley O'Connor Buy 750 $630,000
Exercise of options.
09 Mar 2021 Bradley O'Connor Sell 2 $2,025,000
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Martyn Kenneth Myer Non-Executive ChairmanNon-Executive Director Oct 1999
Mr Myer sits on the Fishermans Bend board, a Victorian Government board charged with developing the Fishermans Bend precinct, and the boards of the Australian Chamber Orchestra and Watertrust Australia Limited. He previously served as Deputy Chancellor of the Council of the University of Melbourne, President of The Myer Foundation, one of two principle Myer Family philanthropic funds, President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of The Florey Institute of Neuroscience and Mental Health, where he participated in the transition of the Institute's research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases Other directorships and interests held by him are Cogstate Inc., Cogstate Health Inc., Cogstate Sports Pty Ltd and Cogstate Spain SL, Fishermans Bend, the Australian Chamber Orchestra and Watertrust Australia Limited
Mr Bradley O'Connor Chief Executive OfficerManaging Director Nov 2005
Mr O'Connor has responsibility for Cogstate's overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business. Prior to taking the position of CEO at Cogstate in 2005, Mr O'Connor joined Cogstate as Chief Financial Officer and Company Secretary in 2004. Prior to that, Mr O'Connor held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers. Other directorships and interests held by him are at Cogstate Inc., Cogstate Health Inc., Cogstate Sports Pty Ltd, Cogstate Healthcare LLC and Cogstate Spain SL.
Ms Ingrid Anne Player Non-Executive Director Aug 2019
Ms Player brings healthcare sector experience and strong commercial expertise to the Board of Cogstate. She has held senior executive roles with Healthscope Ltd, a leading private healthcare provider in Australia, including the former positions of Group Executive Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019. Ms Player also has considerable international commercial and regulatory experience that spans different markets and industries, which she gained in private legal practice in Australia and in The Netherlands. Other directorships and interests held by her are at HealthShare Victoria Cleanaway Waste Management Limited (from 01 March 2021).
Mr Richard van den Broek Non-Executive Director Aug 2010
Mr Van Den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. Prior to his time as an investor in the healthcare industry Mr Van Den Broek had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist.
Mr David Dolby Non-Executive Director Nov 2013
Mr Dolby is founder and CEO of Dolby Family Ventures, a venture capital investment firm focused on technology and life sciences investments in neuro technology and therapeutics targeting Alzheimer's disease. He represents the Dolby Family Trust on a number of technology, scientific research, and consumer products investments focusing on innovation and commercialising intellectual property. Other directorships and interests held by him are at Dolby Laboratories (from 2011), Salk Institute for Biological Sciences (from 2019), Academy Museum of Motion Pictures (from 2019), Tipping Point Community (from 2015), CFO of the Ray and Dagmar Dolby Family Fund (since 2010)
Dr Richard Mohs Non-Executive Director Jan 2017
Dr Mohs is currently Chief Scientific Officer for the Global Alzheimer's Platform (GAP) Foundation, a non-profit devoted to enhancing the speed and quality of Alzheimer's disease research. He also serves as a consultant to academic institutions, foundations and biopharmaceutical companies, and is a member of the Board of Governors for the Alzheimer's Drug Discovery Foundation. Dr Mohs retired from Eli Lilly in 2015, where he held leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer's Drug Development Team. Before joining Eli Lilly, Dr Mohs spent 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Centre. Other directorships and interests held by him are at Alzheimer's Drug Discovery Foundation, Chief Science Officer, Global Alzheimer's Platform Foundation, Consultant for various biotechnology companies, academic institutions and foundations
Ms Kim Wenn Non-Executive Director Nov 2020
Ms Wenn brings technology experience and strong commercial expertise to the Board of Cogstate, with over 30 years experience in innovation roles. Until July 2018, she held the role of Chief Information Officer at Tabcorp Holdings, an ASX50 listed company where Kim led a team of 1,200 technology experts to drive strategic direction through digital transformation. Her experience includes, among other things, business strategy, governance and change management with a focus on digital disruption. She was a director at Volt Bank Limited.
Mr David James Franks Company Secretary Feb 2021
-
Ken Billard Chief Commercial Officer
-
Darren Watson Chief Financial Officer
-
Paul Maruff Chief Innovation Officer
-
Ben Bloomfield Chief Technology Officer
-
David James Franks Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
National Nominees Limited 28,947,551 16.90%
Dagmar Dolby 21,754,028 12.70%
Citicorp Nominees Pty Limited 21,055,219 12.30%
Myer & Myer Pty Ltd 14,424,569 8.40%
HSBC Custody Nominees (Australia) Limited 14,036,981 8.20%
Nebula Neuro Pty Ltd 8,000,000 4.70%
Anacacia Pty Limited 6,771,764 4.00%
Mpyer Investments Pty Ltd 6,061,872 3.50%
BNP Paribas Nominees Pty Ltd 3,906,382 2.30%
Mr Bradley John O'Connor 2,705,929 1.60%
Myer & Myer Pty Ltd I 2,563,000 1.50%
David Dolby Investments Ii Llc 2,202,274 1.30%
Dr Peter Anthony Bick & Ms Melanie Jo Gribble 1,881,026 1.10%
Merrill Lynch (Australia) Nominees Pty Limited 1,833,081 1.10%
Dagmar Dolby I 1,776,500 1.00%
Mr Alistair David Strong 1,320,000 0.80%
Mutual Trust Pty Ltd 1,283,806 0.80%
Beta Gamma Pty Ltd 1,220,000 0.70%
Mr David Alexander Simpson & Mrs Dawn Gentry Simpson 1,163,689 0.70%
Alexander 2006 Llc 1,059,138 0.60%

Profile

since

Note